SAA positivity rate amongst dual LRRK2-GBA1, GBA1 and LRRK2 carriers with Parkinson's disease
Ponger, P.; Nair, A. R.; Noah, N.; Caspell-Garcia, C.; Lafontant, D.-E.; Alcalay, R. N.
Show abstract
We investigated whether people with Parkinson's disease who are dual GBA1+LRRK2 carriers have a milder, LRRK2-like phenotype as previously reported. This was accomplished by comparing clinical features and alpha-synuclein seed amplification assay (SAA) positivity rates between dual GBA1+LRRK2-PD(n=13), GBA1-PD(n=169) and LRRK2-PD(n=175) carriers in a cross-sectional retrospective study of Parkinson's Progression Markers Initiative (PPMI) data. Our results show that GBA1+LRRK2-PD rate(83%) is closer to GBA1-PD rate(87%) rather than LRRK2-PD rate (62%mp-value>0.05). GBA1+LRRK2-PD have both non-motor and motor phenotypic similarity of GBA1-PD(p-value>0.05). This small PPMI cohort indicates that dual GBA1+LRRK2-PD carriers' SAA positivity and phenotype are aligned with GBA1-PD.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Slow Motion Analysis of Repetitive Tapping (SMART) test: measuring bradykinesia in recently diagnosed Parkinson’s disease and idiopathic anosmia 96%
- Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis 95%
- Voice of the patient: Emergence of new motor and non-motor symptoms in early Parkinsons Disease? 95%
Similar papers in this journal
- impaired bed mobility in prediagnostic and de novo Parkinson’s disease 97%
- MAPT allele and haplotype frequencies in Nigerian Africans: population distribution and association with Parkinson’s disease risk and age at onset 97%
- Asymptomatic carriers of the p.A53T SNCA mutation: data from the PPMI study 96%
Similar papers in this journal
Similar papers in this journal
- Prospective role of PAK6 and 14-3-3 gamma as biomarkers for Parkinson's disease 96%
- Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression 95%
- Amplification parameters of the alpha-synuclein seed amplification assay on CSF predict the clinical subtype of Parkinson's Disease at 10-year follow-up 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.